Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eton Pharmaceuticals (ETON) FCF Margin (2019 - 2025)

Historic FCF Margin for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to 52.28%.

  • Eton Pharmaceuticals' FCF Margin rose 236900.0% to 52.28% in Q3 2025 from the same period last year, while for Sep 2025 it was 38.33%, marking a year-over-year increase of 346500.0%. This contributed to the annual value of 2.42% for FY2024, which is 191200.0% down from last year.
  • According to the latest figures from Q3 2025, Eton Pharmaceuticals' FCF Margin is 52.28%, which was up 236900.0% from 42.05% recorded in Q2 2025.
  • Eton Pharmaceuticals' 5-year FCF Margin high stood at 117.02% for Q1 2025, and its period low was 380.9% during Q3 2021.
  • For the 5-year period, Eton Pharmaceuticals' FCF Margin averaged around 5.33%, with its median value being 13.83% (2024).
  • Over the last 5 years, Eton Pharmaceuticals' FCF Margin had its largest YoY gain of 142529700bps in 2021, and its largest YoY loss of 2000000000bps in 2021.
  • Over the past 5 years, Eton Pharmaceuticals' FCF Margin (Quarter) stood at 84.05% in 2021, then skyrocketed by 140bps to 33.28% in 2022, then tumbled by -96bps to 1.3% in 2023, then plummeted by -614bps to 6.67% in 2024, then soared by 884bps to 52.28% in 2025.
  • Its FCF Margin was 52.28% in Q3 2025, compared to 42.05% in Q2 2025 and 117.02% in Q1 2025.